30 January 2015

Grant of Share Options

VERONA PHARMA PLC - Grant of Share Options

PR Newswire

                               Verona Pharma plc

                      ("Verona Pharma" or the "Company")

                            Grant of Share Options

30 January 2015, Cardiff - Verona Pharma plc (AIM: VRP) announces that the
Board has on 29 January 2015 granted options over 32,600,000 ordinary shares
("Options") in the Company to certain of its executive directors and employees,
in accordance with the terms of the Company's share option plans. Half of the
Options will vest on 29 January 2017 and the other half on 29 January 2018.

Of the Options granted, 17,000,000 are to the following executive directors:

Director                  No. of Options granted   Exercise Price of
                                                   Options

Jan-Anders Karlsson, CEO  15,000,000               2.5 pence

Biresh Roy, CFO           2,000,000                2.5 pence

Jan-Anders Karlsson's total beneficial interest in the Company remains
1,709,091 ordinary shares, representing 0.17% of the Company's issued share
capital. Following this grant, Dr. Karlsson holds options over 28,000,000
ordinary shares, representing 2.77% of the Company's issued share capital, with
a range of exercise prices between 2.5 and 15 pence per option.

Following this grant, Biresh Roy holds options over 8,000,000 ordinary shares,
representing 0.79% of the Company's issued share capital, with a range of
exercise prices between 2.2 and 2.5 pence per option.

                                    -Ends-

For further information please contact:

Verona Pharma plc                       Tel: +44 (0) 20 3283 4200
Jan-Anders Karlsson, CEO

N+1 Singer                              Tel: +44 (0)20 7496 3000
Aubrey Powell / Jen Boorer

Notes to Editors

About Verona Pharma plc

Verona Pharma plc is a UK-based clinical stage biopharmaceutical company
focused on the development of innovative prescription medicines to treat
respiratory diseases with significant unmet medical needs, such as COPD, asthma
and cystic fibrosis. Verona Pharma's lead drug, RPL554, is a first-in-class
drug currently in Phase II trials as a nebulised treatment for acute
exacerbations of COPD in the hospital setting. The drug is a
dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both
bronchodilator and anti-inflammatory effects, which are essential to the
improvement of patients with COPD and asthma. Verona Pharma is also building a
broader franchise around RPL554 to maximise its value, both to patients and to
investors. This includes the very significant markets for COPD and asthma
maintenance therapy. The Company is also exploring the potential of the drug in
different diseases, such as cystic fibrosis, where it is in pre-clinical
testing.

For further information please contact:

 

Verona Pharma plc
Jan-Anders Karlsson, CEO
Tel: +44 (0)20 3283 4200
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell / James White
Tel: +44 (0)20 7496 3000

 

 

FTI Consulting
Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins
Tel: +44 (0)20 3727 1000
veronapharma@fticonsulting.com

ICR, Inc. (US Media and Investor enquiries)
James Heins
Tel: +1 203-682-8251
James.Heins@icrinc.com

Stephanie Carrington
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com


Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us